Zelira Therapeutics Limited (OTCMKTS:ZLDAF – Get Free Report)’s stock price was down 13.3% during mid-day trading on Monday . The company traded as low as $0.26 and last traded at $0.26. Approximately 222 shares changed hands during trading, a decline of 67% from the average session volume of 670 shares. The stock had previously closed at $0.30.
Zelira Therapeutics Stock Performance
The business’s 50 day simple moving average is $0.32 and its 200-day simple moving average is $0.35.
Zelira Therapeutics Company Profile
Zelira Therapeutics Ltd is a clinical-stage biotechnology company focused on the development and commercialization of proprietary cannabinoid-based therapies. The company leverages a portfolio of clinical and preclinical drug candidates designed to address unmet medical needs in areas such as chronic pain, autism spectrum disorder, Alzheimer’s disease and sleep disorders. Utilizing patented formulation and delivery platforms, Zelira aims to optimize efficacy and safety profiles of plant-derived cannabinoids.
The company pursues a dual geography strategy through its Australian and North American operations.
Recommended Stories
- Five stocks we like better than Zelira Therapeutics
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Zelira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zelira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
